KDR and esophageal squamous cell carcinoma: Our previous study focused on Apatinib, a novel vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, and elucidated its crucial role in inhibiting progression and metastasis as well as sensitizing paclitaxel in ESCC.